Skip to main content
Howard Safran, MD, Oncology, Providence, RI

HowardPSafranMD

Oncology Providence, RI

Associate Professor, Medicine, Brown University Program in Medicine

Dr. Safran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Safran's full profile

Already have an account?

  • Office

    164 Summit Ave
    # Fain
    Providence, RI 02906
    Phone+1 401-793-2920
    Fax+1 401-444-2127

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1987 - 1990
  • Boston University School of Medicine
    Boston University School of MedicineClass of 1987

Certifications & Licensure

  • RI State Medical License
    RI State Medical License 1993 - 2026
  • MA State Medical License
    MA State Medical License 1989 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top MD Consumers Checkbook

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
  • Adjuvant FOLFOX + nab-paclitaxel (FOLFOX-A)for pancreatic cancer, BrUOG 278: A Brown University oncology research group phase II study. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Working to Close the Cancer Screening Gap Caused by COVID
    Working to Close the Cancer Screening Gap Caused by COVIDMay 17th, 2022
  • Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance Agreement
    Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance AgreementMarch 23rd, 2022
  • Trastuzumab Combined with Trimodality Treatment for HER2-Overexpressing Esophageal Cancer Found to Be Ineffective
    Trastuzumab Combined with Trimodality Treatment for HER2-Overexpressing Esophageal Cancer Found to Be IneffectiveJanuary 22nd, 2022
  • Join now to see all

Professional Memberships